Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for prevention of post-transplant diabetes after kidney transplantation
2016-002023-28Phase 3Active
- Sponsor
- CHU de Besançon
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of vildagliptin in diabetes mellitus (DM), sponsored by CHU de Besançon. Primary endpoint: Proportion of patients with diabetes at 1 year after transplantation. Started Aug 2017; status: active.
02
Drugs
vildagliptin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on 2016-002023-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002023-28.